Attached files
| file | filename |
|---|---|
| 10-K - 10-K - ENANTA PHARMACEUTICALS INC | enta-10k_20200930.htm |
| EX-32.1 - EX-32.1 - ENANTA PHARMACEUTICALS INC | enta-ex321_8.htm |
| EX-31.2 - EX-31.2 - ENANTA PHARMACEUTICALS INC | enta-ex312_11.htm |
| EX-31.1 - EX-31.1 - ENANTA PHARMACEUTICALS INC | enta-ex311_10.htm |
| EX-21.1 - EX-21.1 - ENANTA PHARMACEUTICALS INC | enta-ex211_9.htm |
| EX-10.27 - EX-10.27 - ENANTA PHARMACEUTICALS INC | enta-ex1027_466.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S‑8 (Nos. 333-189217, 333-192935, 333-202257, 333-209542, 333-215011, 333-221988, 333-231375 and 333-231384) of Enanta Pharmaceuticals, Inc. of our report dated November 25, 2020 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10‑K.
/s/ PricewaterhouseCoopers LLP
Boston, Massachusetts
November 25, 2020